IND Submitted for CYT-500

IND Submitted for CYT-500

May 1, 2006

Publication

Article

Oncology NEWS InternationalOncology NEWS International Vol 15 No 5

Volume 15

Issue 5

Cytogen Corporation has submitted an Investigational New Drug (IND) application to the FDA for CYT-500 for the treatment of hormone-refractory prostate cancer.

PRINCETON, New JerseyCytogen Corporation has submitted an Investigational New Drug (IND) application to the FDA for CYT-500 for the treatment of hormone-refractory prostate cancer. CYT-500 targets prostate-specific membrane antigen (PSMA), which is abundantly expressed on the surface of prostate cancer cells. The agent incorporates the same monoclonal antibody used in Cytogen's ProstaScint (capromab pendetide) molecular imaging agent but is linked to a therapeutic payload.

Articles in this issue

NCCN Soft-Tissue Extremity Sarcoma Guidelines Clarify Follow-up Schedule

Genentech Files sBLA for Avastin for First-Line NSCLC Treatment

RFA Effective for Single, Small Hepatocellular Carcinoma

New Imaging, ChemoRT Recommendations From NCCN

Panitumumab Improves PFS in Advanced Colon Ca

Studies Question Watchful Waiting for Some Prostate Ca Pts

Growing Evidence Supports Stem Cell Hypothesis of Cancer

FDA Approves New Every-3-Week Dosing for Aranesp

Telephone Often Delivers News of Breast Cancer Diagnosis

IND Submitted for CYT-500

Lower-Dose Thalidomide Effective in Relapsed or Refractory Multiple Myeloma, With Less Toxicity

Zometa Increases BMD in Breast Ca Patients on Femara

Prostate Cancer Recurrence Linked to Surgeon's Skill

FDA Grants Orphan Drug Status for Cephalon's Lestaurtinib

Automated Voice System Manages Chemo Symptoms

Related Content

Previous results from the study found improvement in the primary end point of PSA-PFS with apalutamide in recurrent prostate cancer.

Apalutamide/ADT Displays Long-Term Efficacy in Recurrent Prostate Cancer

Jonah Feldman

October 20th 2025

Article

Previous results from the study found improvement in the primary end point of PSA-PFS with apalutamide in recurrent prostate cancer.

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD

June 5th 2025

Podcast

Experts weigh in on the practical applications of PSMA PET imaging

Findings from the ENZARAD trial support adding enzalutamide to androgen deprivation therapy for those with positive lymph nodes.

Enzalutamide Combo Shows No MFS Improvement in Advanced Prostate Cancer

Ryan Scott

October 19th 2025

Article

Findings from the ENZARAD trial support adding enzalutamide to androgen deprivation therapy for those with positive lymph nodes.

Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025

Steven Finkelstein, MD, DABR, FACRO

April 15th 2025

Podcast

Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.